-
Share
1,918 Posts.
59
06/10/11
08:32
Share
I don't expect to see much love for small-cap speccies just yet, but some are starting to look appealing:
GTG. Its NASDAQ counterpart GENE finally had a good night in the US - up 7% +. Doesn't mean I'd buy GTG on the open, I'm lurking a bit lower.
Otherwise, for the biotech speccies, news (or unexplained volume spikes) will be the clue.
AHZ, according to the thread, may have an announcement any time, but I haven't verified the likelihood.
Discl: holding AHZ/AHZOA
-